Company intelligence / Profile preview

Microislet

San Diego, CA, USA

Ownership: Private
Development stage: Other

Overview

MicroIslet was a biotechnology company dedicated to developing a cure for insulin-dependent diabetes through the transplantation of encapsulated islet cells. The company's primary technology involved a proprietary microencapsulation process designed to protect islet cells from the recipient's immune system, potentially eliminating the need for chronic immunosuppressive drugs. Their lead program focused on using porcine islet cells as a sustainable source for transplantation. Despite receiving FDA clearance for Phase 1 clinical trials, the company faced significant financial challenges and filed for bankruptcy in 2008.

Therapeutic areas: Endocrinology
Modalities: Cell therapyDevice
Industry: Biotech

Drug pipeline

2 assets

MicroIslet-P

Discontinued

1 more asset in the full pipeline.

Request access →

Partnerships

Duke University Medical Center

Beyond the preview

Go deeper on Microislet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microislet.

Explore the full profile